Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Natus Medical (BABY) Share Price

News coverage about Natus Medical (NASDAQ:BABY) has been trending somewhat positive on Sunday, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Natus Medical earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 46.0782783917725 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

BABY traded down $1.00 during midday trading on Friday, hitting $32.80. 358,046 shares of the company traded hands, compared to its average volume of 422,649. The company has a quick ratio of 2.54, a current ratio of 3.32 and a debt-to-equity ratio of 0.37. The company has a market cap of $1,087.65, a price-to-earnings ratio of 22.62 and a beta of 0.47. Natus Medical has a 52-week low of $28.00 and a 52-week high of $43.60.

How to Become a New Pot Stock Millionaire

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, February 7th. The medical equipment provider reported $0.42 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.54 by ($0.12). The business had revenue of $131.40 million during the quarter, compared to analysts’ expectations of $131.38 million. Natus Medical had a positive return on equity of 11.36% and a negative net margin of 4.05%. The business’s quarterly revenue was up 22.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.51 earnings per share. research analysts forecast that Natus Medical will post 1.63 EPS for the current year.

Natus Medical announced that its board has initiated a stock buyback program on Thursday, February 22nd that permits the company to buyback $30.00 million in shares. This buyback authorization permits the medical equipment provider to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

A number of research analysts have issued reports on BABY shares. BidaskClub lowered shares of Natus Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 6th. Zacks Investment Research lowered shares of Natus Medical from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 11th. Benchmark reiterated a “buy” rating and issued a $49.00 price objective (down previously from $55.00) on shares of Natus Medical in a research note on Tuesday, January 16th. William Blair downgraded shares of Natus Medical from an “outperform” rating to a “market perform” rating in a report on Monday, January 8th. Finally, Roth Capital set a $39.00 price target on shares of Natus Medical and gave the stock a “buy” rating in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $44.33.

In related news, Director Ken Ludlum sold 4,000 shares of the firm’s stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $31.68, for a total transaction of $126,720.00. Following the completion of the sale, the director now directly owns 93,825 shares in the company, valued at $2,972,376. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 5.50% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Natus Medical (BABY) Share Price” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Insider Buying and Selling by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with's FREE daily email newsletter.

Leave a Reply